Who
Howard G. Welgus
Director
Company insider
Files Form 4 as: Chief Medical Officer, Arcutis Biotherapeutics.
In numbers
- Trades disclosed
- 310
- Buys
- 0
- Sells
- 59
- Bought
- $0
- Sold
- $8.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Feb 2020
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $5,361822 at $6.52 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $7,6451,018 at $7.51 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $19K2,254 at $8.63 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $127K4,728 at $26.93 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —822 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,018 at $0.00 | filing |
| 15 Oct 2026filed 19 Oct 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,254 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $5,361822 at $6.52 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $7,6531,019 at $7.51 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $19K2,255 at $8.63 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —822 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,019 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,255 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Sold | $114K4,730 at $24.18 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —822 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,019 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,255 at $0.00 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $5,359822 at $6.52 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $7,6531,019 at $7.51 | filing |
| 15 Sep 2026filed 17 Sep 2026 | ARQT Arcutis BiotherapeuticsBiotechnology | SEC FORM 4 Code M | $19K2,255 at $8.63 | filing |
News
Arcutis Biotherapeutics (ARQT) Gets New Rating Uprgades from 2 Analysts; Shares ClimbARQT · insidermonkey.com · 20 Oct 2026
0 headlines in the last 90 days name Howard G. Welgus; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.